Chemiesynth (Vapi) Ltd Sets AGM Agenda for Capital Expansion

The company is seeking approval for a Rs 15 crore private placement and an increase in authorized share capital to Rs 18.25 crore.

Reader Takeaway: Fundraise supports expansion, while related party transaction limits require investor monitoring for arm's-length compliance.

What just happened

Chemiesynth (Vapi) Ltd has scheduled its 40th Annual General Meeting for September 30, 2026. The board has placed several critical proposals before shareholders, most notably a plan to raise Rs 15 crore through the issuance of 1.50 crore Unlisted Non-Convertible Cumulative Redeemable Preference Shares (NCRPS) at a face value of Rs 10 each. These instruments carry a 5% cumulative dividend rate and a tenure of seven years.

Why this matters

To facilitate this fundraising, the company is proposing to expand its authorized share capital from Rs 3.25 crore to Rs 18.25 crore. The funds are earmarked for long-term growth, working capital requirements, and business expansion. The primary subscribers for this issuance include CS Specialty Chemicals Pvt Ltd, CS Fine Interchem Pvt Ltd, and other identified persons.

Governance and Related Party Transactions

The AGM will also seek member approval for various related party transactions. The proposed maximum annual limits include Rs 15 crore for CS Speciality Chemicals Pvt Ltd, Rs 10 crore for CS Fine Interchem Pvt Ltd, and Rs 5 crore for transactions involving promoters Mr. Satish B. Zaveri and Mr. Sandip S. Zaveri. Shareholders are also expected to adopt a new set of Articles of Association to align with current regulatory frameworks.

What to track next

Investors should monitor the voting outcome on the related party transaction limits and the successful allotment of the preference shares following the AGM, as these developments will define the company’s near-term balance sheet structure and operational linkages with group entities.